ERBB2 and breast cancer: The present study found that TNBC and HER2+ breast cancer patients have a high abundance of TILs infiltration, mainly immune infiltrated, while luminal breast cancer patients have a low abundance of TILs infiltration, mainly immune desert and immune excluded, further suggesting that the tumor immune microenvironment of breast cancer patients may affect the efficacy of neoadjuvant chemotherapy.